Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance

Pulmonary Pharmacology and Therapeutics

Volumn 13, Issue 6, 2000, Pages 249-256

  Cazzola, Mario ^a   Matera, Maria Gabriella ^b   Noschese, Paolo ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Antimicrobial resistance; Continuous antibiotic infusion; Lower respiratory tract infections; Parenteral antibiotic administration; Pharmacokinetic pharmacodynamic interrelationship

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG TISSUE LEVEL; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0033673264     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2000.0253     Document Type: Review

References (42)

1. Epidemiology of drug resistance: For a post-antimicrobial era
2. Antibiotic resistance: Lessons for the future
3. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance
4. Antibiotic resistance is selected primarily in our patients
5. The cost of antibiotic resistance-from the perspective of a bacterium
6. The best of times, the worst of times. The global challenge of antimicrobial resistance
7. Origins and evolution of antibiotic resistance
8. Selective compartments for resistant microorganisms in antibiotic gradients
9. The antibiotic selective process: Concentration-specific amplification of low-level resistant populations
10. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Selecting th antibiotic. Selecting the antibiotic
11. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics
12. Update on clindamycin: New pharmacokinetic and pharmacodynamic data
13. Choosing an antibiotic on the basis of pharmacodynamics
14. AUIC - A general target for the optimization of dosing regimens of antibiotics?
15. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin
16. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
17. Grepafloxacin: Pharmacokinetics and tissue penetration
18. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
19. Pharmacodynamic interactions of antibiotics alone and in combination
20. The importance of antibiotic pharmacokinetics in critical illness
21. Pharmacokinetics and prescribing in the elderly
22. Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against Gram-negative bacilli
23. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients
24. Pharmacokinetics in acute illness
25. Pharmacokinetics of drugs used in critically ill adults
26. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care
27. Altered aminoglycoside pharmacokinetics in the critically ill
28. Pharmacokinetics of antibiotics in critically ill patients
29. Farmacocinetica degli antibiotici: Somministrazione orale e parenterale, distribuzione nell'organismo, eliminazione
30. New concepts in the pulmonary disposition of antibiotics
31. Bactericidal effect of ceftriaxone versus imipenem plus cilastin in bronchial secretion
32. Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: Implication for treatment of community-acquired lower respiratory tract infections
33. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
34. Relevance of the Alexander Project: Pharmacodynamic considerations
35. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
36. In vitro selective antibiotic concentrations of β-lactams for penicillin-resistant Streptococcus pneumoniae population
37. Interrelationship between pharmacokinetics and pharmacodynamics in the design of dosage regimens for treating acute exacerbations of chronic bronchitis
38. Strategies to minimize the development of antibiotic resistance
39. Beta-lactam antibiotics: Is continuous infusion the preferred method of administration?
40. Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations
41. The pharmacodynamics of β-lactams
42. A comparison of cefoperazone, ceftizoxime and ceftriaxone by integrating pharmacokinetic and serum bactericidal activity data